Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin in type 2 diabetes mellitus with chronic kidney disease (real-world registry)
ChiCTR2500114675Phase 4Completed
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of henagliflozin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Proportion of subjects with normal or improved urine albumin-to-creatinine ratio (UACR) at week 48. Started Dec 2025; status: completed.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500114675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114675.